cbdMD, Inc.

YCBD

US12482W4087

Pharmaceuticals

Market Closed - Nyse Other stock markets 04:00:00 2026-02-13 pm EST			5-day change	1st Jan Change
0.7012 ^USD	+2.36%		-24.02%	-48.06%

Feb. 02	Cbdmd, Inc.'S Herbal Oasis Expands into Louisiana with Morales Beverage Group Following Strong Texas Momentum	CI
Jan. 29	CbdMD, Inc. Strengthens Regulatory Science Platform to Support Emerging Regulatory Cannabinoid Evaluation Pathways	CI

CbdMD, Inc. Reports Earnings Results for the Full Year Ended September 30, 2025

Published on 12/19/2025 at 04:06 pm EST

S&P Capital IQ

CBDMD, INC.

+2.36%

cbdMD, Inc. reported earnings results for the full year ended September 30, 2025. For the full year, the company reported sales was USD 19.19 million compared to USD 19.92 million a year ago. Revenue was USD 19.19 million compared to USD 19.48 million a year ago.

Net loss was USD 2.04 million compared to USD 3.7 million a year ago. Basic loss per share from continuing operations was USD 1.09 compared to USD 14.29 a year ago.

Latest news about cbdMD, Inc.

Feb. 02	Cbdmd, Inc.'S Herbal Oasis Expands into Louisiana with Morales Beverage Group Following Strong Texas Momentum	CI
Jan. 29	CbdMD, Inc. Strengthens Regulatory Science Platform to Support Emerging Regulatory Cannabinoid Evaluation Pathways	CI
Jan. 14	cbdMD announces strategic acquisition of Bluebird Botanicals	RE
Jan. 13	CbdMD, Inc. acquired assets of Gaia Botanicals, LLC for $1 million.	CI
Dec. 19	CbdMD, Inc., Q4 2025 Earnings Call, Dec 19, 2025
Dec. 19	CbdMD, Inc. Reports Earnings Results for the Full Year Ended September 30, 2025	CI
Dec. 19	Investors Hope for Rate Cut Following Subdued Inflation as US Futures Mixed in Friday's Premarket Session	MT
Dec. 19	CbdMD Insider Sold Shares Worth $1,276,842, According to a Recent SEC Filing	MT
Dec. 19	Wall Street Set to Open Little Changed as Investors Await Home Sales, Consumer Sentiment Data	MT
Dec. 19	Investors Hope for Rate Cut Following Subdued Inflation as US Futures Mixed in Friday's Premarket Session	MT
Dec. 18	CbdMD, Inc. Auditor Raises 'Going Concern' Doubt	CI
Dec. 18	CbdMD, Inc. announced that it has received $2.25 million in funding	CI
Nov. 21	CbdMD reports preliminary unaudited fourth quarter results	RE
Nov. 21	CbdMD, Inc. Reports Preliminary Earnings Results for the Fourth Quarter and Year Ended September 30, 2025	CI
25-10-09	Cbdmd's Herbal Oasis Expands Its Florida Footprint with Bevtalk Distribution Partnership	CI

Chart cbdMD, Inc.

Duration

Period

YCBD: Dynamic Chart

Company Profile

cbdMD, Inc. is a cannabidiol (CBD) company. The Company has a comprehensive line of United States produced, THC-free CBD products, including NSF Certified for Sport products, as well as its new Full Spectrum products. The Company's flagship brands include cbdMD and Paw CBD, as well as its functional mushroom brand ATRx Labs. Its cbdMD brand includes high-grade, premium CBD products including CBD tinctures, CBD gummies, CBD topicals, CBD capsules, CBD sleep aids and CBD drink products including its Herbal Oasis Social Tonic and an array of Farm Act compliant Delta 9 products. Its Paw CBD brand of pet products includes veterinarian-formulated products including tinctures, chews, topicals products in varying strengths, and its ATRx brand of natural functional mushroom support. Its cbdMD, Paw CBD and ATRx products are distributed through its e-commerce websites, third party e-commerce sites, select distributors and marketing partners as well as a variety of brick-and-mortar retailers.

Employees

Sector

Pharmaceuticals

Calendar

Aug. 18 - Q3 2026 Earnings Release (Projected)

More about the company